This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Newman Ferrara LLP Announces Investigation Of DUSA Pharmaceuticals Inc.

Newman Ferrara LLP is investigating potential claims against the board of directors of DUSA Pharmaceuticals Inc. (“DUSA”) (Nasdaq: DUSA) concerning the proposed acquisition of DUSA by Sun Pharmaceutical Industries Ltd. (“Sun Pharma”).

On November 8, 2012, DUSA announced that it had entered into a definitive agreement to be acquired by Sun Pharma in an all cash deal valued at approximately $230 million. Under the terms of the agreement, Sun Pharma will commence a tender offer to acquire all outstanding shares of DUSA stock from DUSA’s shareholders at a price of $8.00 in cash for each share of DUSA stock owned. Prior to announcement of the proposed deal, DUSA common stock had increased in value by over 77% since November 2011. The proposed deal was announced ahead of DUSA’s third quarter corporate highlights and financial results that were scheduled to be released the morning of November 8, 2012.

DUSA’s Board of Directors has unanimously approved the proposed deal and has recommended that DUSA’s shareholders tender their shares to Sun Pharma pursuant to the tender offer.

Newman Ferrara LLP’s investigation concerns whether DUSA’s Board of Directors has breached its fiduciary duties to act in the best interests of DUSA’s shareholders and to take all necessary steps to ensure that DUSA’s shareholders receive the maximum value readily available for their shares of DUSA common stock.

Concerned investors are encouraged to contact Newman Ferrara attorney Roy Shimon at (212) 619-5400 or rshimon@nfllp.com to discuss this investigation, their rights, or potential remedies.

Newman Ferrara maintains a multifaceted practice based in New York City with attorneys specializing in complex commercial and multi-party litigation, securities fraud and shareholder litigation, consumer protection, civil rights, and real estate. For more information, please visit the firm website at www.nfllp.com.

CONTACT:Newman Ferrara LLPAttorney:Roy Shimon1250 Broadway, 27 th Fl.New York, NY 10001 rshimon@nfllp.comTel. 212.619.5400

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs